News

Alcon Sees Surge in Shares Following Positive Results for Dry-Eye Treatment

1 Mins read

Swiss pharmaceutical company Alcon experienced a notable rise in shares on Wednesday after announcing positive results for its dry-eye disease treatment in two trials.

At 0834 GMT, Swiss shares of Alcon were up 4.8% at CHF69.46, reaching a high of CHF70.20.

Alcon confirmed on Tuesday that its candidate drug, AR-15512, successfully achieved its primary goals with statistical significance in treating dry-eye disease. The company plans to submit a new drug application to the U.S. Food and Drug Administration by mid-2024.

According to a research note by Citi analysts, the drug has demonstrated faster efficacy compared to its competitors Restasis and Xiidra, positioning it for a substantial market share in the United States. Analysts project an estimated earnings-per-share increase of approximately 3% for every $100 million in sales by 2026. The U.S. dry-eye treatment market, where Alcon is listed, is valued between $1.5 billion and $2 billion, as stated by Citi.

Additionally, Alcon successfully met secondary goals, including the promotion of rapid and sustained tear production.

Related posts
News

Economic Calendar for the Week of June 29th

1 Mins read
Notable earnings: 🦗Trending NowBest Forex Trading Robots To Invest In 2022 U.S. economic events: Chicago PMI, Fed Speeches: Bostic, Goolsbee, Dallas Fed…
News

$TRUMP and other meme coins won't be protected by SEC, Commissioner Hester Peirce says

3 Mins read
LAS VEGAS — Now that the SEC is out of the business of regulating meme coins, investors shouldn’t expect any guidance on…
News

Man charged in New York with 3-week kidnapping to try to steal Bitcoin

1 Mins read
NEW YORK (Reuters) -A grand jury has indicted a 37-year-old cryptocurrency investor accused of kidnapping a business partner inManhattan’s upscale Soho neighborhood…

Leave a Reply

Your email address will not be published. Required fields are marked *

30 − = 25